Suven Life Sciences’ clinical drug candidate SUVN-502 has completed all the long term chronic studies like 6-month rat toxicological (tox), 9-month dog tox and developmental tox studies like prenatal development tox in rats and rabbits, embryo-fetel development tox in rats and male fertility tox in rats very successfully and demonstrated very high margin of safety (MOS). These regulatory tox studies are essential for FDA approval to initiate human phase 2a clinical trials in patient population.
SUVN-502 has been tested in human Phase 1 trials in Switzerland and demonstrated to be very safe at all doses and durations tested with excellent bioavailability. The next stage of testing will be proof of concept phase 2a clinical trials in patients with Alzheimer’s/Schizophrenia disease.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1835.25 |
| Dr. Reddys Lab | 1306.55 |
| Cipla | 1362.95 |
| Zydus Lifesciences | 941.35 |
| Lupin | 2455.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: